PVCT Provectus Biopharmaceuticals - Comparative study shows Rose Bengal more efficiant than bevacizumab in treating corneal neovasculari - PVCT Provectus Biopharmaceuticals - InvestorVillage


PVCT Provectus Biopharmaceuticals
This is a semi-private group. You are free to browse messages, but you must be a member of this group to post messages. Join This Group

Group: PVCT Provectus Biopharmaceuticals   /  Message Board  /  Read Message

 
 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  5934 of 5995  at  5/10/2021 9:26:26 AM  by

leave_the_gun


Comparative study shows Rose Bengal more efficiant than bevacizumab in treating corneal neovascularization.


  Introduction
To compare the efficacy of bevacizumab and rose bengal photodynamic therapy (RB-PDT) in the treatment of corneal neovascularization (CNV).

Material and methods
The study design included the induction of CNV by suture placement in three groups of New Zealand rabbits: (1) a group with CNV without any treatment; (2) a group treated with subconjunctival injection of bevacizumab (25 mg/eye); (3) a group treated with intravenous injection of rose bengal and exposed to 532 nm photodynamic therapy. For 4 weeks, the animals were followed up by slit-lamp to analyze the extent of CNV, evaluate the corneal protein secondary structure, and determine the oxidative stress index (OSI).

Results
After 4 weeks, traces of neovascularization were observed only in the bevacizumab treated group with grade 0.5. The contents of -helix and -sheet were 17% and 61% in CNV, 32%, and 46% in bevacizumab and 40% and 36% in RB-PDT groups vs. 43% and 35% for the control group. Moreover, the percentage changes in the total oxidative status (TOS) for CNV, bevacizumab and RB-PDT groups were 97.1%, 14.6%, and 1.0%, respectively, with respect to the control. The total antioxidant status (TAC) showed no significant changes (p > 0.05) for both treated groups. The percentage of changes in OSI was 15.9% and 1.3% in bevacizumab, and RB-PDT treated groups compared with the control group.

Conclusions
Both modes of treatment were effective in the regression of CNV, but RB-PDT was more efficient than bevacizumab by improving the corneal protein secondary structure and the oxidative stress.
 
=====
 
 Bevacizumab, sold under the commercial name Avastin, is on the World Health Organization's List of Essential Medicine. Depending on which indication it's being used to treat, it can cost upwards of $100,000 per year per patient treated. Counties like Canada and the UK have placed restrictions on it's use because it's too expensive.
 
Avastin generates over $7 BILLION dollars in sales for Roche annually. Yet, here we are with a better product that could cost patients significantly less.
 
It's just a matter of time, folks. 


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 7     Views: 0
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
5935 Re: Comparative study shows Rose Bengal more efficiant than bevacizumab in treating corneal neovascularization. keahou 3 5/10/2021 10:03:09 AM
5936 And LTG; It Looks like we see evidence of using Rose Bengal intravenously: Take_The_Canolis 4 5/10/2021 2:28:43 PM


Financial Market Data provided by
.
Loading...